Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices

Wednesday, September 10, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

IRVINE, Calif., Sept. 10 Masimo (Nasdaq: MASI),the inventor of Pulse CO-Oximetry and Measure-Through-Motion-and-Low-Perfusionpulse oximetry, today announced that all customers purchasing the MasimoRadical-7, the company's flagship product, will now receive Desat Index 3DAlarm as a standard feature.

Conventional pulse oximeters typically alarm based on large and isolateddrops in oxygen saturation values, known as a "desaturation". However,published research has shown that a cycle of moderate desaturations has beenshown to precede respiratory failure in hospitalized patients(1,2). MasimoDesat Index 3D Alarm enables advanced notification of these conditions, basedon clinician-specified severity and number of desaturations occurring in aspecified period of time.

Michael O'Reilly, MD, Masimo Executive Vice President of Medical Affairs,stated; "When combined with the proven ability of Masimo Signal ExtractionTechnology (SET) to dramatically reduce false desaturation alarms and improvethe detection of true desaturations, Masimo Desat Index 3D Alarm advancespatient care by allowing earlier intervention to prevent adverse respiratoryevents."

Joe Kiani, Chairman and CEO of Masimo, stated; "Masimo has been sellingDesat Index 3D Alarm as an option for almost three years. In light of oursoon-to-be released breakthrough innovation, noninvasive and continuoushemoglobin monitoring technology, we are pleased to now offer Desat Index 3DAlarm as a standard feature."

(1) Continuous Pulse Oximeter Monitoring for Inapparent Hypoxemia afterLong Bone Fractures. Wong MW, Tsui HF, Yung SH, Chan KM, Cheng JC. Journalof Trauma-Injury Infection & Critical Care. 56(2):356-362, February 2004.

(2) Occurance and Mechanisms of Sudden Oxygen Desaturation in Infants WhoSleep Face Down. Patel AL, Paluszynska D, Harris KA, Thach BT.Pediatrics. 2003Apr;111(4 Pt 1):e328-32.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies thatsignificantly improve patient care-helping solve "unsolvable" problems. In1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulseoximetry, known as Masimo SET, which virtually eliminated false alarms andincreased pulse oximetry's ability to detect life-threatening events. Morethan 100 independent and objective studies demonstrate Masimo SET provides themost reliable SpO2 and pulse rate measurements even under the most challengingclinical conditions, including patient motion and low peripheral perfusion.In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasiveblood constituent monitoring platform that can measure many blood constituentsthat previously required invasive procedures. Masimo Rainbow SET continuouslyand noninvasively measures total hemoglobin (SpHb(TM)), oxygen content(SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), andPVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusionindex (PI), allowing early detection and treatment of potentiallylife-threatening conditions. Founded in 1989, Masimo has the mission of"Improving Patient Outcomes and Reducing Cost of Care by Taking NoninvasiveMonitoring to New Sites and Applications." Additional information about Masimoand its products may be found at

Forward Looking Statements

This press release may include forward-looking statements. These forward-looking statements are based on current expectations about future eventsaffecting us and are subject to uncertainties and factors, all of which aredifficult to predict and many of which are beyond our control, including:risks related to our assumption that the addition of Desat Index 3D Alarms asa standard feature on the Masimo Radical-7 will lead to additional devicesales, as well as other factors discussed in the "Risk Factors" section of ourquarterly report on Form 10-Q for the qua

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store